腺苷对经皮冠状动脉介入治疗心肌保护作用研究  

A Clinical Study of Adenosine on Percutaneous Transluminal Coronary Angioplasty

作　　者：刘向儒[1] 张晓红[1] 谭小军[1] 陈小亮[1] 容志毅[1] 

机构地区：[1]郴州市第一人民医院心内科,湖南郴州423000

出　　处：《湘南学院学报（医学版）》2007年第1期32-34,共3页Journal of Xiangnan University（Medical Sciences）

摘　　要：目的研究就腺苷对经皮冠状动脉介入治疗(PCI)术后心肌损伤标志物的影响,并探讨其对PCI术中心肌保护作用、减少术后并发症的可能性。方法所有患者随机分2组。A组为治疗组,在对患者进行按常规PCI操作治疗时,分别在球囊扩张前和支架植入后2次冠脉内弹丸式注射腺苷300μg。不使用腺苷按常规PCI操作进行治疗。两组患者均在PCI术前、术后6、122、4、487、2 h抽静脉血检测肌钙蛋白I(cTnI),对比其差别。结果两组患者在性别、年龄、冠心病相关危险因素和药物治疗等方面差异无统计学意义,在病变部位、程度、病变的复杂性、支架植入数目等方面差异无统计学意义。腺苷治疗组PCI术后cTnI升高比例和cTnI>2.0μg/L例数较传统手术组明显减少(P<0.01)。结论腺苷具有明显的心肌保护作用,值得临床推广。Objective To investigate if adenosine can improve the myocardial protection after percutaneous transluminal coronary angioplasty.Methods 171 patients with CHD were divided into two groups（adenosine A group and control B group）at random, Cardiac troponin Ⅰ （cTnⅠ） were measured in two groups before PCI,6,12, 24,48,72 hours after PCI.Results No significant difference was shown between two groups in cTnI before PCI. The percentage of cTnI rising above the cutoff was 11% in group A and 24% in group B. Group A was superiors to group B（ P 〈 0.01 ） after PCI. Conclusion Adenosine can reduce myocardial injury in PCI. It can be regarded as a reliable method in PCI.

关 键 词：腺苷 经皮冠状动脉介入治疗 肌钙蛋白 

分 类 号：R816.2[医药卫生—放射医学]